177 related articles for article (PubMed ID: 36650539)
1. Impacts of the preceding cancer-specific health-related quality of life instruments on the responses to the subsequent EQ-5D-5L.
Izumi S; Hagiwara Y; Matsuyama Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K
Health Qual Life Outcomes; 2023 Jan; 21(1):3. PubMed ID: 36650539
[TBL] [Abstract][Full Text] [Related]
2. Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer.
Hagiwara Y; Shiroiwa T; Taira N; Kawahara T; Konomura K; Noto S; Fukuda T; Shimozuma K
Health Qual Life Outcomes; 2020 Nov; 18(1):354. PubMed ID: 33143687
[TBL] [Abstract][Full Text] [Related]
3. A head-to-head comparison of EQ-5D-5L and SF-6D in Dutch patients with fractures visiting a Fracture Liaison Service.
Li N; Boonen A; van den Bergh JP; van Kuijk SMJ; Wyers CE; van Oostwaard M; Vranken L; Bours SPG; Hiligsmann M
J Med Econ; 2022; 25(1):829-839. PubMed ID: 35674412
[TBL] [Abstract][Full Text] [Related]
4. Internal Responsiveness of EQ-5D-5L and EORTC QLQ-C30 in Dutch Breast Cancer Patients during the First Year Post-Surgery: A Longitudinal Cohort Study.
Vrancken Peeters NJMC; van Til JA; Huberts AS; Siesling S; Husson O; Koppert LB
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893073
[TBL] [Abstract][Full Text] [Related]
5. Assessing the validity of EQ-5D-5L in people with head & neck cancer: Does a generic quality of life measure perform as well as a disease-specific measure in a patient population?
Davies A; Waylen A; Leary S; Thomas S; Pring M; Janssen B; Beynon R; Lang S; Schimansky S; Hurley K; Ness A
Oral Oncol; 2020 Feb; 101():104504. PubMed ID: 31835074
[TBL] [Abstract][Full Text] [Related]
6. Measuring the Time to Deterioration for Health-Related Quality of Life in Patients With Metastatic Breast Cancer Using a Web-Based Monitoring Application: Longitudinal Cohort Study.
Brusniak K; Feisst M; Sebesteny L; Hartkopf A; Graf J; Engler T; Schneeweiss A; Wallwiener M; Deutsch TM
JMIR Cancer; 2021 Oct; 7(4):e25776. PubMed ID: 34636732
[TBL] [Abstract][Full Text] [Related]
7. Mapping EORTC-QLQ-C30 onto EQ-5D-5L Index in Indonesian Cancer Patients.
Perwitasari DA; Purba FD; Candradewi SF; Marwin M; Permata A; Ulfa Faza MB; Septiantoro BP; Kaptein AA
Asian Pac J Cancer Prev; 2023 Apr; 24(4):1125-1130. PubMed ID: 37116132
[TBL] [Abstract][Full Text] [Related]
8. "The validity of the EQ-5D-5L in measuring quality of life benefits of breast reconstruction".
Kouwenberg CAE; Kranenburg LW; Visser MS; Busschbach JJ; Mureau MAM
J Plast Reconstr Aesthet Surg; 2019 Jan; 72(1):52-61. PubMed ID: 30270015
[TBL] [Abstract][Full Text] [Related]
9. Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores.
Meunier A; Soare A; Chevrou-Severac H; Myren KJ; Murata T; Longworth L
Appl Health Econ Health Policy; 2022 Jan; 20(1):119-131. PubMed ID: 34554442
[TBL] [Abstract][Full Text] [Related]
10. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
[TBL] [Abstract][Full Text] [Related]
11. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
[TBL] [Abstract][Full Text] [Related]
12. Validity of EQ-5D-5L health-related quality of life questionnaire in self-reported diabetes: evidence from a general population survey.
Jankowska A; Młyńczak K; Golicki D
Health Qual Life Outcomes; 2021 May; 19(1):138. PubMed ID: 33952271
[TBL] [Abstract][Full Text] [Related]
13. Comparing the psychometric properties of the EQ-5D-3L and EQ-5D-5L in cancer patients in Korea.
Kim SH; Kim HJ; Lee SI; Jo MW
Qual Life Res; 2012 Aug; 21(6):1065-73. PubMed ID: 21947656
[TBL] [Abstract][Full Text] [Related]
14. Validation and comparison of 15-D and EQ-5D-5L instruments in a Spanish Parkinson's disease population sample.
García-Gordillo M; del Pozo-Cruz B; Adsuar JC; Sánchez-Martínez FI; Abellán-Perpiñán JM
Qual Life Res; 2014 May; 23(4):1315-26. PubMed ID: 24258254
[TBL] [Abstract][Full Text] [Related]
15. Mapping the EORTC QLQ-C30 onto the EQ-5D-5L index for patients with paroxysmal nocturnal hemoglobinuria in France.
Wojciechowski P; Wdowiak M; Hakimi Z; Wilson K; Fishman J; Nazir J; Toumi M
J Comp Eff Res; 2023 May; 12(5):e220178. PubMed ID: 37052120
[No Abstract] [Full Text] [Related]
16. Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD).
Yang F; Lau T; Lee E; Vathsala A; Chia KS; Luo N
Eur J Health Econ; 2015 Dec; 16(9):1019-26. PubMed ID: 25519850
[TBL] [Abstract][Full Text] [Related]
17. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study.
Hernandez G; Garin O; Dima AL; Pont A; Martí Pastor M; Alonso J; Van Ganse E; Laforest L; de Bruin M; Mayoral K; Serra-Sutton V; Ferrer M;
J Med Internet Res; 2019 Jan; 21(1):e10178. PubMed ID: 30672744
[TBL] [Abstract][Full Text] [Related]
18. Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in Colorectal Cancer Patients.
Ameri H; Yousefi M; Yaseri M; Nahvijou A; Arab M; Akbari Sari A
J Gastrointest Cancer; 2020 Mar; 51(1):196-203. PubMed ID: 30977049
[TBL] [Abstract][Full Text] [Related]
19. Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D-5L and HUI-3 indices in patients with head and neck cancer.
Noel CW; Stephens RF; Su JS; Xu W; Krahn M; Monteiro E; Goldstein DP; Giuliani M; Hansen AR; de Almeida JR
Head Neck; 2020 Sep; 42(9):2277-2286. PubMed ID: 32333829
[TBL] [Abstract][Full Text] [Related]
20. Mapping the Chinese Version of the EORTC QLQ-BR53 Onto the EQ-5D-5L and SF-6D Utility Scores.
Liu T; Li S; Wang M; Sun Q; Chen G
Patient; 2020 Oct; 13(5):537-555. PubMed ID: 32382953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
